Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: deuterium-containing therapeutics - Concert Pharmaceuticals

Drug Profile

Research programme: deuterium-containing therapeutics - Concert Pharmaceuticals

Alternative Names: C-10068; C-20081; C-21246; C-21359; CTP-221; D-apremilast; D-boceprevir; D-cilostazol; D-darunavir; D-iloprost; D-lenalidomide; D-linezolid; D-ranolazine

Latest Information Update: 10 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Concert Pharmaceuticals; GSK
  • Class Neuroprotectants; Organic deuterium compounds; Oxazolidinones; Small molecules; Sodium compounds; Sulfonamides; Synthetic prostaglandins
  • Mechanism of Action Angiogenesis inhibitors; Epoprostenol agonists; GABA A receptor modulators; Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; HIV protease inhibitors; Immunomodulators; Interleukin 1 beta stimulants; Interleukin 10 stimulants; Partial fatty acid oxidation inhibitors; Platelet aggregation inhibitors; Protein 30S ribosomal subunit inhibitors; Pyruvate dehydrogenase stimulants; Sigma-1 receptor agonists; Tumour necrosis factor inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Cardiovascular disorders; Epilepsy; Hepatitis C; HIV infections; Inflammation; Kidney disorders; Methicillin-resistant Staphylococcus aureus infections; Neuropathic pain; Pulmonary arterial hypertension

Most Recent Events

  • 06 Mar 2023 Concert Pharmaceuticals has been acquired by Sun Pharmaceutical Industries
  • 11 Mar 2022 Terran Biosciences acquires Concert Pharmaceuticals' CNS therapeutics portfolio and intellectual property rights
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top